Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice-Reference-Cited by-同舟云学术

Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice

Published:2016-11 Issue:11 Volume:1862 Page:2054-2062
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

de Oliveira Monique C.,Gilglioni Eduardo H.,de Boer Bouke A.,Runge Jurgen H.,de Waart Dirk R.,Salgueiro Clairce L.,Ishii-Iwamoto Emy L.,Oude Elferink Ronald P.J.,Gaemers Ingrid C.

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference41 articles.

1. The metabolic syndrome—a new worldwide definition;Alberti;Lancet,2005

2. Hormone replacement therapy (HRT)—risks and benefits;Barrett-Connor;Int. J. Epidemiol.,2001

3. Expression and activation of the farnesoid X receptor in the vasculature;Bishop-Bailey;Proc. Natl. Acad. Sci. U. S. A.,2004

4. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance;Camporez;Endocrinology,2013

5. Positive regulation of osteogenesis by bile acid through FXR;Cho;J. Bone Miner. Res.,2013

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear factor interleukin 3 and metabolic dysfunction-associated fatty liver disease development;Communications Biology;2024-07-24

2. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets;Signal Transduction and Targeted Therapy;2024-04-26

3. Interaction between Per- and Polyfluorinated Substances (PFAS) and Acetaminophen in Disease Exacerbation—Focusing on Autism and the Gut–Liver–Brain Axis;Toxics;2024-01-03

4. The emerging role of bile acids in white adipose tissue;Trends in Endocrinology & Metabolism;2023-11

5. Nuclear factor interleukin 3 and metabolic dysfunction-associated fatty liver disease development;2023-09-18